Burkly Linda 4

What Happened Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine (EDIT), sold 731 shares on June 3, 2026. The filing reports a weighted average price of $2.70 per share for a total value of approximately $1,975. This was a sale (not a purchase) and is presented as a routine disposition to meet tax obligations rather than an active, discretionary trade.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (timely filing).
• Reported price/total: $2.70 weighted average; total proceeds ≈ $1,975.
• Execution detail: Trades were executed in multiple transactions at prices ranging $2.7010–$2.7050 (footnote F2); the filing offers to provide full trade-level details on request.
• Reason/footnote: Sale effected under a durable automatic sales instruction plan adopted July 3, 2023, to cover tax withholding for restricted stock units that vested June 2, 2026; the sale was not a discretionary trade by the reporting person (footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing.

Context This was a tax-withholding sale tied to RSU vesting, which is common and typically not interpreted as a signal about the insider’s view of the company. Sales under automatic plans or for tax withholding are routine; purchases would be more indicative of a positive insider signal.